Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct Psilocin Administration and First-Ever Psychedelic Botanical Drug Candidates

The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco VANCOUVER, BC, Nov. 2, 2021 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally…

Source